



Etiology of Severe Acute Respiratory Infections in ICU-Admitted Patients During the COVID-19 Pandemic in Iran: A Single Center Study

Marzieh Jamalidoust ¹, Gholamreza Pouladfar ^{1,*}, Maryam Eskandari ¹, Nasrin Aliabadi ¹, Nahid Heydari Marandi ¹, Mandana Namayandeh ¹, Mazyar Ziyaeyan ¹

¹ Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding Author: Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, 71937-11351, Shiraz, Iran. Email: pouladfar_ghr@hotmail.com

Received: 11 April, 2024; Revised: 24 July, 2024; Accepted: 3 September, 2024

Abstract

Background: Acute respiratory infections (ARI) caused by a wide range of etiologies represent a significant public health challenge worldwide.

Objectives: In this study, we aimed to evaluate the characteristics of ARI caused by various respiratory pathogens among patients admitted to intensive care units (ICUs) in a referral hospital in Iran during the first four waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

Methods: A total of 395 patients with ARI were enrolled, all hospitalized in the ICUs of Nemazi Teaching Hospital, affiliated with Shiraz University of Medical Sciences in Shiraz, Iran, over a 13-month period from April 2020 to June 2021. Real-time polymerase chain reaction (RT-PCR) assays were used to detect SARS-CoV-2, influenza viruses, respiratory syncytial virus (RSV), *Mycoplasma*, and *Chlamydia* in nasopharyngeal fluid (NPS) samples. The demographic and clinical data, including underlying diseases, were also considered.

Results: Of the 395 patients, 209 (53.7%) were male, and the mean age was 32 ± 27 years. An etiology was detected in 63 (16%) patients, with 53 testing positive for SARS-CoV-2 and 5 each for *Chlamydia* and *Mycoplasma*. No RSV or influenza infections were detected. The highest rate of COVID-19 was observed among adults aged 36 to 65 years (5.31%), while the lowest rate was in children under 5 years old (0.3%). Shortness of breath was the most common symptom in SARS-CoV-2-infected patients (P -value ≤ 0.001). Of the total patients, 146 (37%) had at least one underlying disease, with diabetes being the most common (8.1%).

Conclusions: The absence of RSV and influenza infections, along with a notable number of *Chlamydia* and *Mycoplasma* infections during the first four waves of the SARS-CoV-2 pandemic, emphasizes the importance of continuous surveillance of the etiologies of ARI during respiratory pandemics. This information is critical for guiding appropriate infection control measures and selecting empirical antibiotic regimens.

Keywords: ARIs, Viral Respiratory Infections, Bacterial Respiratory Infections, ICU-Admitted Patients

1. Background

Globally, acute respiratory diseases are the most frequent illnesses across all age groups. Typically, these diseases are confined to the upper airways and are self-limiting; however, a small percentage of cases may progress to lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia. Pneumonia, consistently ranking among the most severe conditions causing illness and death worldwide, is characterized as an acute inflammation of the lung parenchyma and is caused by numerous microorganisms, including

bacteria, viruses, and fungi (1, 2). Bacterial pathogens such as *Streptococcus pneumoniae* and *Hemophilus influenzae*, along with viral agents like respiratory syncytial virus (RSV) and influenza virus, are major contributors to pneumonia. Fortunately, vaccines are available and effective against the two bacteria and the influenza virus (3).

Clinicians treating patients with acute respiratory infections (ARI) in various hospital settings must be aware of the most common pathogens responsible for ARIs and their association with severe disease presentations to ensure appropriate patient

management and treatment. Identifying the causative agents of respiratory infections is also vital for public health surveillance. However, few studies have explored the distribution of respiratory pathogens across different hospital settings (e.g., outpatient clinics, emergency rooms, inpatient wards, and intensive care units) and the environmental, etiological, and host factors that predispose patients to severe disease, including hospitalization or intensive care admission.

Some studies conducted in different geographical regions have shown that the incidence of viral infections in critical care settings varies and has often been underreported. However, over recent years, there has been an increase in reported cases, likely due to the use of more sensitive, rapid, and accurate modern diagnostic methods (4, 5).

Bacteria are the most prevalent cause of lower LRTIs, with *Streptococcus pneumoniae* accounting for nearly half of all documented cases of community-acquired pneumonia (CAP) where the pathogen is identified (6). However, following the pandemics of H1N1 influenza in 2009 and COVID-19 in 2019, the number of viral infections requiring intensive care unit (ICU) admission has been on the rise (7).

Prior to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the prevalence of virus-associated LRTIs requiring ICU admission ranged from 16% to 49%, with RSV and influenza being the most frequently identified viruses (8, 9). *Mycoplasma* is a common cause of upper respiratory infections (URIs) and Lower respiratory infection (LRI), and in children, hospitalization is required in 18% of cases (10). Additionally, respiratory infections due to *Chlamydia pneumoniae* are significant bacterial agents in ICU settings, commonly diagnosed through serological tests. Studies show that *C. pneumoniae* accounts for 6% to 22% of LRI in children and adults (11).

Utilizing more advanced viral molecular diagnostic tools, it is now possible to identify etiologies that might not have been detectable in the past. This is particularly important for patients admitted to the ICU, who are more likely to have underlying medical conditions that could make them more susceptible to infections.

2. Objectives

In this study, we aimed to use accurate molecular tests to determine the rate of SARS-CoV-2 infection, as well as other respiratory viral (*Influenza* and RSV) and bacterial (*Mycoplasma* and *C. pneumoniae*) infections, in ICU-admitted patients during the first four waves of the SARS-CoV-2 pandemic in Iran.

3. Methods

3.1. Study Design

In this cross-sectional study, we considered 395 patients from April 1, 2020, to June 16, 2021, who were suspected or had clinically confirmed respiratory infections at Nemazi Hospital in Shiraz. The inclusion criteria were as follows: (1) being hospitalized in the ICU, (2) signing informed consent forms to participate in the study, and (3) being a resident of Fars province. The survey covered the four peaks of respiratory infections during the study period: The first peak from February to May 2020, the second from May to June 2020, the third from October to November 2020, and the fourth from March to April 2021. The full list of symptoms used to classify probable respiratory infection cases is included in the study e-questionnaire.

3.2. TaqMan Real-time PCR Assay

Sterile Dacron swabs were used to obtain nasopharyngeal fluid (NPS) samples from the patients. Respiratory specimens were collected by trained nurses regardless of the clinical severity. The collected specimens were stored on ice and transported immediately to the laboratory for viral and bacterial screening. Real-time PCR assays were conducted within 1 - 2 hours of sample collection to detect the nucleic acids of SARS-CoV-2, RSV, *Influenza*, *Mycoplasma*, and *Chlamydia* (12). Patient data were retrieved from the hospital information system (HIS), including demographic features such as age, sex, and clinical symptoms (fever, shortness of breath, cough, and fatigue). These data were collected via a standardized case reporting form for each enrolled patient.

3.3. Statistical Analysis

Descriptive statistics were used to classify the study group based on respiratory infection PCR results. Numbers and percentages were reported for the classified variables. There was no missing data. The chi-square test was employed to compare qualitative variables among subgroups of patients. A significance level of ≤ 0.05 was considered. To evaluate the contribution of specific viruses and bacteria without regard to the presence of other pathogens, the model included all tested respiratory viruses and their two-way interactions. All statistical analyses were performed using SPSS software, version 26.

3.4. Ethical Considerations

Table 1. Demographic Data and Infections Type of Iranian Intensive Care Unit Hospitalized Patients with Acute Respiratory Infections in COVID-19 Comparing Non-COVID ICUs (N = 395)

Characteristics	All Patients	COVID-ICUs	Non-COVID ICUs	Non-determined ICUs	P-Value
Number (%)	395	30 (7.6)	306 (77.4)	59 (15)	-
Mean age (y) ± SD	32.46 ± 27.45	50.90 ± 19.06	29.88 ± 27.16	36.43 ± 28.87	0.001 ^{a, b}
Male/female ratio	209/180 (1.16)	19/11 (1.72)	163/137 (1.19)	27/32 (0.45)	-
SARS-CoV-2 infections	53 (84)	14 (46.7)	31 (10.13)	8 (13.6)	< 0.0001 ^{a, c}
<i>Mycoplasma</i> infections	4 (6.25)	0	4 (1.3)	0	0.53 ^c
<i>Chlamydia</i> infections	5 (8)	1 (3.4)	3 (0.98)	1 (1.7)	0.24 ^c
SARS-CoV-2/ <i>Mycoplasma</i> coinfection	1 (1.56)	1 (3.4)	0	0	0.001 ^{a, c}

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^a P < 0.05.

^b Chi-square test was employed.

^c Kruskal-Wallis test was employed.

This study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (ethic code: [IR.SUMS.REC.1400.268](#)).

4. Results

4.1. Demographic Data of the Patients

A total of 395 ICU patients were enrolled in the study, comprising 209 (53.7%) male subjects. Samples were collected from hospitalized patients over a 13-month period. The mean age of the patients was (32.46 ± 27.45) years, with the youngest being 1 day old and the oldest 100 years old.

Out of the total patients, 30 (7.6%) were admitted to the COVID-19 ICU, 306 (77.5%) were admitted to non-COVID-19 ICUs, and in 59 (14.9%) cases, it was unclear which ICU the patient was admitted to. The demographic characteristics of these participants and their ICU admissions are summarized in [Table 1](#).

[Table 1](#) demonstrates that the average age of patients admitted to COVID-19 ICUs was significantly higher compared to those admitted to non-COVID ICUs. While the male-to-female ratio was higher in COVID-19 ICUs, no statistically significant difference was found between the two groups.

As shown in [Table 2](#), individuals aged 36 - 65 years constituted more than 29% of the participants in the study, making them the largest age group. They were followed by children aged ≤ 5 years, who comprised nearly 26% of the participants.

4.2. Infection Types Amongst the Intensive Care Unit-Admitted Patients

Out of the 395 patients admitted to ICUs, 63 (16%) had a single type of infection. In 53 of these cases (84%), the infection was caused by the SARS-CoV-2 virus, while 10 cases (16%) were identified as bacterial infections. Among the bacterial infections, 5 patients were diagnosed with *Chlamydia* and 5 with *Mycoplasma*. None of the ICU-admitted patients tested positive for RSV or influenza ([Table 1](#)).

Notably, one COVID-19 ICU patient aged 65 years or older was diagnosed with a dual infection of SARS-CoV-2 and *Mycoplasma*. Additionally, 31 ARI patients in non-COVID ICUs were found to be positive for COVID-19.

Compared to children admitted to the ICU (aged ≤ 15 years), adults (aged ≥ 15 years) were more likely to have a SARS-CoV-2 infection (19.6% vs. 3.9%), while the prevalence of bacterial infections was similar in both groups (2.9% vs. 1.9%).

4.3. Clinical Presentation of Respiratory Infections in Intensive Care Unit-Admitted Patients

As shown in [Figure 1](#), respiratory symptoms were compared between ICU-admitted patients with and without confirmed molecular infections. Overall, shortness of breath was the most common symptom among SARS-CoV-2-infected patients and was significantly higher (P ≤ 0.001). Additionally, coughing, joint pain, and dizziness were more prevalent among those who tested positive for infections, though these were not statistically significant.


4.4. Underlying Conditions in Intensive Care Unit-Admitted Patients

Underlying conditions were also considered in this study. A total of 146 (36.96%) patients had underlying

Table 2. Prevalence of Mono- and/or Co-infections in Iranian Patients Hospitalized in Intensive Care Units in 2020 - 2021 Among Different Age Groups (N = 395)^a

Age (y)	Total ICU Patients	Total Mono-infection	Viral Mono- infection	Bacterial Mono- infection	Co-infection
0 - 5	101 (25.56)	4 (6.34)	1 (2)	3 (30)	0
6 - 15	54 (13.67)	5 (7.93)	5 (9)	0	0
16 - 35	68 (17.21)	12 (19.04)	11 (21)	1 (10)	0
36 - 65	115 (29.11)	26 (41.26)	23 (43)	3 (30)	0
> 65	57 (14.43)	16 (25.39)	13 (25)	3 (30)	1
Total	395	63	53	10	1

Abbreviation: ICU, intensive care unit.

^a Values are expressed as No. (%) unless otherwise indicated.**Figure 1.** Comparison of clinical symptoms in PCR positive and negative intensive care unit (ICU)-admitted patients. *** shortness of breath significantly higher in PCR positive patients.

diseases, with diabetes being the most prevalent, affecting 32 (8.1%) patients. This was followed by cardiovascular disease in 25 (6.32%) patients, chronic disease in 20 (5.06%), hypertension in 14 (3.54%), malignancies in 9 (2.27%), immunosuppressive conditions and myasthenia gravis (MG) in 6 (1.51%), liver disease in 10 (1.26%), and coronary heart disease in 10 (1.26%) patients.

Diabetes was the most frequent underlying disease among patients with confirmed respiratory infections.

Statistical analysis indicated that respiratory infections were non-significantly higher among certain groups of ICU-admitted patients with underlying conditions (Figure 2).

5. Discussion

Acute respiratory infections are one of the leading causes of mortality and morbidity worldwide, and increased attention has been given to the surveillance of ARIs among high-risk hospitalized patients following the COVID-19 pandemic. This research contributes to filling the knowledge gap regarding the extent of acute respiratory illness and provides robust data on the rate of ARIs in ICU settings. In our study, 16% of cases were classified as confirmed respiratory infections based on positive real-time PCR assays.

Severe acute respiratory syndrome coronavirus 2 was identified as the primary pathogen in ICU patients, while RSV and influenza were not detected in any of the




Figure 2. Prevalence of respiratory infections among Iranian patients with underlying diseases

patients. In contrast, before the COVID-19 era, viral respiratory pathogens such as influenza, RSV, and adenoviruses were the most frequently identified in patients with severe respiratory infections (13). However, by mid-2020, most countries had implemented strict infection control protocols, resulting in a significant drop in influenza and RSV cases (14-16).

Non-pharmaceutical interventions including home isolation, hand hygiene, cough etiquette, universal mask usage, and the reduction of unnecessary social activities were cited as the primary reasons for the changing patterns and declining incidence of some respiratory viral infections, including influenza and RSV, during the pandemic. Viral interference, a process that may affect viral infection patterns, has also been considered as an explanation for the decreased incidence of certain respiratory viral infections (17, 18).

The findings of this research indicated a higher rate of SARS-CoV-2 infection among adults, consistent with other studies. This could be due to decreased pre-existing immunity and increased expression and affinity of ACE-2 receptors, which facilitate viral entry (19, 20).

It is widely acknowledged that ICUs have a heightened risk of nosocomial infections, with respiratory infections being the most common. Furthermore, the risk of nosocomial respiratory infection is 20 times higher in patients requiring mechanical ventilation (21). Several studies have shown

that the overall rate of bacterial infection among hospitalized COVID-19 patients was estimated to be 7.1%, with 3.5% being hospital-acquired infections and 15.5% developing nosocomial secondary bacterial infections. Despite this, 74% of patients received broad-spectrum antibiotics (22-24). In this study, the frequency of *Mycoplasma* and *Chlamydia* infections in ICU settings was relatively high (2.5%) during the pandemic. Some studies on bacterial co-infections in COVID-19 patients have indicated that *Acinetobacter baumannii* and *Klebsiella* infections are common (25-27), while this study identified *Mycoplasma* infections as secondary bacterial co-infections in ICU patients.

Severe outcomes among hospitalized patients with ARI were most strongly associated with the presence of pre-existing chronic diseases (28). Glezen et al. demonstrated that respiratory viruses frequently cause severe acute respiratory conditions, often resulting in hospitalization for individuals with underlying conditions (29).

Although 40% of the ICU-admitted patients in this study had underlying conditions, there was no significantly higher rate of confirmed infections among patients with or without underlying diseases.

Although it is insufficient to rely solely on clinical symptoms to identify the causative agents of respiratory tract infections (30), this study revealed that shortness of breath was the most common symptom, significantly higher in PCR-positive patients. Additionally, no

significant difference in clinical symptoms was observed between confirmed cases of bacterial and viral infections in patients with ARI.

Our study had several important limitations. The sample size was limited, and all samples were baseline, without follow-up data. Lower respiratory infections encompass various diseases caused by a wide range of pathogens, which may exhibit different spatiotemporal patterns. This study assessed a restricted number of infectious agents.

5.1. Conclusions

During the COVID-19 pandemic, this study emphasized the importance of accurate identification and diagnosis of respiratory illnesses in ICUs. Our findings indicated that SARS-CoV-2 was the dominant viral infection among ICU patients, with no non-COVID viral infections such as influenza or RSV detected during the study period. However, treatable bacterial infections, including *Chlamydia* and *Mycoplasma*, were identified in ICU patients.

This research contributes to a better understanding of the ecology of viral infections during the COVID-19 pandemic and the interplay between viral and bacterial infections in ICUs.

Acknowledgements

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, and also the Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour for editorial assistance.

Footnotes

Authors' Contribution: Gh. R. P. and M. Z.: Conceptualized and designed the study; M. J. and M. E.: Collected the data, drafted and revised the manuscript; N. H.: Performed the molecular tests; M. N. and N. A.: Initially analyzed and interpreted the data; M. J. and Gh. R. P.: Critically reviewed and revised the manuscript and all authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any parts of the work will be appropriately investigated and resolved.

Conflict of Interests Statement: The authors declare no competing interests.

Data Availability: The data that support the findings of this study are available on request from the

corresponding author.

Ethical Approval: The study was approved by the Research Ethics Committee of Shiraz University of Medical Sciences. It adhered to the ethical principles and national norms and standards for conducting medical research in Iran, with the approval code IR.SUMS.REC.1400.268.

Funding/Support: The study is supported by Shiraz University of Medical Sciences (grant number: 21735).

Informed Consent: Informed consent was obtained from all participants.

References

1. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. *Med Clin North Am.* 2019;**103**(3):487-501. [PubMed ID: 30955516]. <https://doi.org/10.1016/j.mcna.2018.12.008>.
2. Jamalidoust M, Jalil M, Ashkan Z, Sharifi M, Hemmati R, Dashti AS, et al. COVID 19 infection clinical features in pediatric patients in Southwestern Iran: a cross-sectional, multi-center study. *BMC Infect Dis.* 2023;**23**(1):828. [PubMed ID: 38007434]. [PubMed Central ID: PMC10675973]. <https://doi.org/10.1186/s12879-023-08720-z>.
3. Leone M, Bouadma L, Bouhemad B, Brissaud O, Dager S, Gibot S, et al. Hospital-acquired pneumonia in ICU. *Anaesth Crit Care Pain Med.* 2018;**37**(1):83-98. [PubMed ID: 29155054]. <https://doi.org/10.1016/j.accpm.2017.11.006>.
4. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. *Intensive Care Med.* 2006;**32**(7):1022-9. [PubMed ID: 16791664]. [PubMed Central ID: PMC7080063]. <https://doi.org/10.1007/s00134-006-0202-x>.
5. Piralla A, Rovida F, Girello A, Premoli M, Mojoli F, Belliato M, et al. Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU. *PLoS One.* 2017;**12**(6). e0178926. [PubMed ID: 28591230]. [PubMed Central ID: PMC5462403]. <https://doi.org/10.1371/journal.pone.0178926>.
6. Cantan B, Luyt CE, Martin-Loeches I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit. *Semin Respir Crit Care Med.* 2019;**40**(4):488-97. [PubMed ID: 31585475]. [PubMed Central ID: PMC7117087]. <https://doi.org/10.1055/s-0039-1693497>.
7. O'Halloran AC, Holstein R, Cummings C, Daily Kirley P, Alden NB, Yousey-Hindes K, et al. Rates of Influenza-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death by Race and Ethnicity in the United States From 2009 to 2019. *JAMA Netw Open.* 2021;**4**(8). e2121880. [PubMed ID: 34427679]. [PubMed Central ID: PMC8385599]. <https://doi.org/10.1001/jamanetworkopen.2021.21880>.
8. Nguyen C, Kaku S, Tuter D, Kuschner WG, Barr J. Viral Respiratory Infections of Adults in the Intensive Care Unit. *J Intensive Care Med.* 2016;**31**(7):427-41. [PubMed ID: 25990273]. <https://doi.org/10.1177/0885066615585944>.
9. Schnell D, Gits-Muselli M, Canet E, Lemiale V, Schlemmer B, Simon F, et al. Burden of respiratory viruses in patients with acute respiratory failure. *J Med Virol.* 2014;**86**(7):1198-202. [PubMed ID: 24108695]. [PubMed Central ID: PMC7167001]. <https://doi.org/10.1002/jmv.23760>.
10. Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev.* 2004;**17**(4):697-728. table of

- contents. [PubMed ID: 15489344]. [PubMed Central ID: PMC523564]. <https://doi.org/10.1128/CMR.17.4.697-728.2004>.
11. Hammerschlag MR. Chlamydia pneumoniae and the lung. *Eur Respir J*. 2000;**16**(5):1001-7. [PubMed ID: 11153568]. <https://doi.org/10.1183/09031936.00.16510010>.
 12. Soltani A, Jamalidoust M, Hosseinpour A, Vahedi M, Ashraf H, Yousefinejad S. First molecular-based detection of SARS-CoV-2 virus in the field-collected houseflies. *Sci Rep*. 2021;**11**(1):13884. [PubMed ID: 34230585]. [PubMed Central ID: PMC8260644]. <https://doi.org/10.1038/s41598-021-93439-7>.
 13. Horton KC, Dueger EL, Kandeel A, Abdallat M, El-Kholy A, Al-Awaidy S, et al. Viral etiology, seasonality and severity of hospitalized patients with severe acute respiratory infections in the Eastern Mediterranean Region, 2007-2014. *PLoS One*. 2017;**12**(7). e0180954. [PubMed ID: 28704440]. [PubMed Central ID: PMC5509236]. <https://doi.org/10.1371/journal.pone.0180954>.
 14. Letafati A, Aghamirmohammadali FS, Rahimi-Foroushani A, Hasani SA, Mokhtari-Azad T, Yavarian J. No human respiratory syncytial virus but SARS-CoV-2 found in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran. *J Med Virol*. 2022;**94**(7):3096-100. [PubMed ID: 35229318]. [PubMed Central ID: PMC9088699]. <https://doi.org/10.1002/jmv.27685>.
 15. Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. *Infect Drug Resist*. 2023;**16**:661-75. [PubMed ID: 36743336]. [PubMed Central ID: PMC9897071]. <https://doi.org/10.2147/IDR.S396434>.
 16. Takeuchi H, Kawashima R. Disappearance and Re-Emergence of Influenza during the COVID-19 Pandemic: Association with Infection Control Measures. *Viruses*. 2023;**15**(1). [PubMed ID: 36680263]. [PubMed Central ID: PMC9862942]. <https://doi.org/10.3390/v15010223>.
 17. Wu A, Mihaylova VT, Landry ML, Foxman EF. Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study. *Lancet Microbe*. 2020;**1**(6):e254-62. [PubMed ID: 33103132]. [PubMed Central ID: PMC7580833]. [https://doi.org/10.1016/s2666-5247\(20\)30114-2](https://doi.org/10.1016/s2666-5247(20)30114-2).
 18. Jamalidoust M, Eilami O, Ashkan Z, Ziyaeyan M, Aliabadi N, Habibi M. The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers. *Virology*. 2023;**20**(1). <https://doi.org/10.1186/s12985-023-02156-2>.
 19. Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR. Epidemiology of coronavirus respiratory infections. *Arch Dis Child*. 1983;**58**(7):500-3. [PubMed ID: 6307189]. [PubMed Central ID: PMC1628163]. <https://doi.org/10.1136/adc.58.7.500>.
 20. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA*. 2020;**323**(23):2427-9. [PubMed ID: 32432657]. [PubMed Central ID: PMC7240631]. <https://doi.org/10.1001/jama.2020.8707>.
 21. Andrews CP, Coalson JJ, Smith JD, Johanson WJ. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury. *Chest*. 1981;**80**(3):254-8. [PubMed ID: 7273874]. <https://doi.org/10.1378/chest.80.3.254>.
 22. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis*. 2020;**71**(9):2459-68. [PubMed ID: 32358954]. [PubMed Central ID: PMC7197596]. <https://doi.org/10.1093/cid/ciaa530>.
 23. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect*. 2020;**26**(10):1395-9. [PubMed ID: 32603803]. [PubMed Central ID: PMC7320692]. <https://doi.org/10.1016/j.cmi.2020.06.025>.
 24. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect*. 2021;**27**(1):83-8. [PubMed ID: 32745596]. [PubMed Central ID: PMC7836762]. <https://doi.org/10.1016/j.cmi.2020.07.041>.
 25. Contou D, Claudinon A, Pajot O, Micaelo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive Care*. 2020;**10**(1):119. [PubMed ID: 32894364]. [PubMed Central ID: PMC7475952]. <https://doi.org/10.1186/s13613-020-00736-x>.
 26. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. *BMC Infect Dis*. 2020;**20**(1):646. [PubMed ID: 32873235]. [PubMed Central ID: PMC7461753]. <https://doi.org/10.1186/s12879-020-05374-z>.
 27. Baskaran V, Lawrence H, Lansbury LE, Webb K, Safavi S, Zainuddin NI, et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. *J Med Microbiol*. 2021;**70**(4). [PubMed ID: 33861190]. [PubMed Central ID: PMC8289210]. <https://doi.org/10.1099/jmm.0.001350>.
 28. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. *J Infect Dis*. 1999;**179**(1):25-30. [PubMed ID: 9841818]. <https://doi.org/10.1086/314567>.
 29. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. *JAMA*. 2000;**283**(4):499-505. [PubMed ID: 10659876]. <https://doi.org/10.1001/jama.283.4.499>.
 30. Kuchar E, Miskiewicz K, Nitsch-Osuch A, Szenborn L. Pathophysiology of Clinical Symptoms in Acute Viral Respiratory Tract Infections. *Adv Exp Med Biol*. 2015;**857**:25-38. [PubMed ID: 25786400]. [PubMed Central ID: PMC7121097]. https://doi.org/10.1007/5584_2015_110.